Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 7Phase 3 3Phase 1/2 2Phase NA 1Phase EARLY_PHASE1 1

Status

Completed 26Terminated 6Withdrawn 3Active not recruiting 3Unknown 2Recruiting 2Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Other hematologic neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 72Breast Neoplasms 63Neoplasms 59Leukemia, Myeloid, Acute 59Multiple Myeloma 53Colorectal Neoplasms 48Lymphoma 46Recurrence 45Carcinoma, Hepatocellular 45Stomach Neoplasms 43Pancreatic Neoplasms 40Neoplasm Metastasis 39Prostatic Neoplasms 34Melanoma 34Leukemia 30Lymphoma, Non-Hodgkin 27Lymphoma, B-Cell 27Lung Neoplasms 27Precursor Cell Lymphoblastic Leukemia-Lymphoma 24Glioblastoma 24Ovarian Neoplasms 23Lymphoma, Large B-Cell, Diffuse 21Esophageal Neoplasms 21Carcinoma, Renal Cell 20Myelodysplastic Syndromes 19Leukemia, Lymphocytic, Chronic, B-Cell 19Hematologic Neoplasms 19Colonic Neoplasms 19Head and Neck Neoplasms 18Lymphoma, Mantle-Cell 17

Interventions

Vincristine 1Prednisone 1Flow Cytometry 1Doxorubicin 1Cyclophosphamide 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unknown × Lymphoma, Large-Cell, Anaplastic × Clear all
NCT02274584 2014-10-24

CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)

Peking University

Phase 1/2 Unknown
20 enrolled
Lymphoid

Hodgkin Disease, Lymphoma, Lymphoma, Large-Cell, Anaplastic

NCT00363090 2013-09-20

Alemtuzumab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV T-Cell Non-Hodgkin's Lymphoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
84 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡